Abemaciclib - Eli Lilly

Drug Profile

Abemaciclib - Eli Lilly

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY-2835219; Verzenio

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Dana-Farber Cancer Institute; Eli Lilly; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Brain cancer; Glioblastoma; Liposarcoma; Mantle-cell lymphoma; Pancreatic cancer; Solid tumours
  • Phase I Cancer; Non-small cell lung cancer

Most Recent Events

  • 27 Jul 2018 The Committee for Medicinal Products for Human Use of EMA grants a positive opinion for marketing authorization of abemaciclib for the treatment of Breast cancer
  • 01 Jun 2018 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 01 Jun 2018 Efficacy and adverse events data from the phase III MONARCH-2 trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top